Drug intelligence / Profile preview

OP-I-01

Development stage: Preclinical
Lead developer: Omikron
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

OP-I-01 is an investigational injectable solution being developed by Omikron Italia for the treatment of vascular indications. It is currently part of the company's research and development pipeline with an anticipated market launch date of 2028. As of early 2024, Omikron Italia has not publicly disclosed the specific molecular target, mechanism of action, or the clinical phase of development for this candidate. It is one of several vascular-focused injectable products, alongside OP-I-02 and OP-I-03, currently in the company's mid-to-long-term development strategy.

Beyond the preview

Go deeper on OP-I-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OP-I-01.

Explore the full profile